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Background. Cannabinoids have deleterious effects on prefrontal cortex (PFC)-mediated functions and multiple evidences link
the endogenous cannabinoid (endocannabinoid) system, cannabis use and schizophrenia, a disease in which PFC functions are
altered. Nonetheless, the molecular composition and the physiological functions of the endocannabinoid system in the PFC are
unknown. Methodology/Principal Findings. Here, using electron microscopy we found that key proteins involved in
endocannabinoid signaling are expressed in layers V/VI of the mouse prelimbic area of the PFC: presynaptic cannabinoid CB1
receptors (CB1R) faced postsynaptic mGluR5 while diacylglycerol lipase a (DGL-a), the enzyme generating the
endocannabinoid 2-arachidonoyl-glycerol (2-AG) was expressed in the same dendritic processes as mGluR5. Activation of
presynaptic CB1R strongly inhibited evoked excitatory post-synaptic currents. Prolonged synaptic stimulation at 10Hz induced
a profound long-term depression (LTD) of layers V/VI excitatory inputs. The endocannabinoid -LTD was presynaptically
expressed and depended on the activation of postsynaptic mGluR5, phospholipase C and a rise in postsynaptic Ca2+ as
predicted from the localization of the different components of the endocannabinoid system. Blocking the degradation of 2-AG
(with URB 602) but not of anandamide (with URB 597) converted subthreshold tetanus to LTD-inducing ones. Moreover,
inhibiting the synthesis of 2-AG with Tetrahydrolipstatin, blocked endocannabinoid-mediated LTD. All together, our data show
that 2-AG mediates LTD at these synapses. Conclusions/Significance. Our data show that the endocannabinoid -retrograde
signaling plays a prominent role in long-term synaptic plasticity at the excitatory synapses of the PFC. Alterations of
endocannabinoid -mediated synaptic plasticity may participate to the etiology of PFC-related pathologies.
Citation: Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, et al (2007) Molecular Components and Functions of the Endocannabinoid System in
Mouse Prefrontal Cortex. PLoS ONE 2(8): e709. doi:10.1371/journal.pone.0000709
INTRODUCTION
The endogenous cannabinoid (endocannabinoid, eCB) system is
emerging as one of the most ubiquitous activity dependent
regulatory system in the CNS [1,2]. The wide expression of
cannabinoid CB1 receptors (CB1R) explains the ever growing list
of functions attributed to the eCB-system (for extensive reviews see
[1–3]. Thus, pharmacological agents acting on the various
elements of the eCB system have a great potential to treat a wide
range of pathologies including food intake disorders, chronic pain,
emesis, insomnia, glaucoma, glioma, motor disorders, stroke and
severe psychiatric conditions such as depression, autism and
schizophrenia [2,4–6].
Schizophrenia is a chronic and severe brain disease that has its
symptomatic onset in early adulthood and affects multiple
cognitive and behavioral functions. Prefrontal dopaminergic and
glutamatergic dysfunctions have been proposed to participate to
the etiology of schizophrenia [7]. Deregulations of the eCB system
in the prefrontal cortex (PFC) may also participate to this disease
[8]. The PFC participates to the organization and the planning of
voluntary movements and to the programming of actions [9]. The
PFC allows the storage of information and their subsequent use for
decision taking and the elaboration of strategies. In particular, the
PFC has been proposed to play a crucial role in short-term
working memory (the ability to keep events ‘‘in mind’’ to prepare
organized behavioral responses, [9]). Cannabis derivatives alter
prefrontal functions such as working memory and a number of
studies suggest that cannabis use can cause or exacerbate
psychoses and may increase the risk of developing schizophrenia
[10–12]. Furthermore, increased density of binding at CB1R in
the PFC of schizophrenics has been demonstrated [13,14] while
other studies have shown increased anandamide levels in the CSF
or blood of schizophrenics [15–17]. In addition genetic studies
have shown an association between the gene encoding CB1R
(CNR1) and schizophrenia [18,19]. Finally, the genetic ablation of
CB1R alters the schizophrenia-like behavioral effects of the
dissociative anesthetic and non-competitive NMDAR antagonist
phencyclidine [8,20]. Thus multiple evidences point toward a role
of the eCB-system in the pathophysiological functions of the PFC
[8,21]. Although the PFC appears as a structure of choice to study
the eCB system, how CB1Rs play a role in synaptic transmission
and plasticity within the PFC is poorly documented [22–24]. Here,
we used electron microscopy and patch-clamp techniques to
describe the molecular components of the eCB system and how
they participate to long-term synaptic plasticity at pyramidal
synapses in layers V/VI synapses of the mice prelimbic area of the
PFC.
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RESULTS
Ultrastructural localization of components of the
eCB system in mice prefrontal cortex pyramidal cells
Confocal and electron microscopy approaches were used to
identify the localization of proteins known to participate to eCB-
mediated retrograde signaling in the striatum and the hippocam-
pus [1,25,26,27,28,29]. Thus in layers V/VI synapses of the
prelimbic area of the prefrontal cortex (PrPFC), we searched for
the presence of: CB1R, mGluR5, a postsynaptic receptor to
glutamate which activation releases eCB [28] and DAG lipase 1a
(DGL-a ), an enzyme that produces 2-AG.
Double immunofluorescence for mGluR5 and CB1R showed
no colocalization of both proteins (Fig 1A, A’). Thus, mGluR5
Figure 1. Immunocytochemical localization of mGluR5 and CB1R in the prelimbic prefrontal cortex (prPFC). (A) Double confocal
immunofluorescence showed no colocalization of both proteins. mGluR5 immunoreactivity was distributed in the neuropil throughout cortical
layers, but the staining was more evident in apical dendrites of layers V/VI pyramidal neurons heading for the superficial layers. High CB1R
immunoreactivity was in layers II/III, deeper part of layer V and throughout layer VI (A: enlargement of A). The lack of CB1R labeling showed mGluR5
immunoreactivity in layers I, IV and in the upper part of layer V. (B–F). Electron microscopy of the localization of mGluR5 (DAB immunoreaction
product) and CB1R (silver-intensified gold particles) in prPFC cortical layers V/VI. mGluR5 immunoreactivity was in dendritic profiles and spines (s).
Typically, CB1R immunopositive synaptic terminals (T) made asymmetric synapses with mGluR5-immunoreactive dendritic spines (s). Note metal
particles localizing CB1R (arrows) at perisynaptic and extrasynaptic sites relative to presynaptic membrane specializations of axonal synaptic boutons.
Scale bars in A,A’: 100 mm; B,C,E,F: 0.33 mm; D:0.20 mm.
doi:10.1371/journal.pone.0000709.g001
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labeling was in cell bodies and ascending dendritic bundles of deep
cortical pyramidal neurons (Fig 1A). Furthermore, a mesh-like
immunoreactivity was also observed in the neuropil throughout
the prefrontal cortical layers (Fig 1A). The CB1R expression
pattern was layer specific, as immunofluorescence was mostly
restricted to layers II/III and V/VI (Fig 1A, A’). Immunopositive
dotty elements and thin processes took up the neuropil of the
labeled layers where they intermingled with mGluR5 immunore-
active somatodendritic domains (Fig 1A, A’).
The precise localization of CB1R and mGluR5 in cortical layers
V/VI was studied by double immunoelectron microscopy (Fig 1B–
F). As expected, mGluR5 immunoreactivity was in small dendritic
spines. Although DAB immunodeposits diffused within the
profiles, postsynaptic densities of asymmetrical synapses were
observed in mGluR5 positive spines receiving CB1R immunola-
beled synaptic terminals. Furthermore, the CB1R silver-intensified
gold particles were closely placed to membranes away from
presynaptic specializations of the axon terminals.
To define the subcellular distribution of DGL-a with respect to
CB1R and mGluR5, we performed double immunoelectron
microscopy by immunoperoxidase for DGL-a and by a preembed-
ding immunogold method for either mGluR5 or CB1R (Fig 2A–
D). Indeed, DGL-a immunoreactivity colocalized with mGluR5 in
dendritic and spiny domains (Fig 2A, B). As expected, mGluR5
immunoparticles were perisynaptic or far excluded from post-
synaptic specializations. Conversely, CB1R immunolabeling was
on membranes of axon terminals making synapses with DGL-
a immunoreactive dendritic spines (Fig 2C, D). CB1R immuno-
particles were left out of the presynaptic specializations of the
synapses. Quantified data are summarized Table 1.
Cannabinoids acting at presynaptic CB1R inhibits
glutamatergic transmission in the mice prefrontal
cortex
The presence of CB1R immunolabeling at the axon terminals of
(presumably glutamatergic) asymmetrical synapses prompted us to
test at the functional level the effects of CB agonists at the
glutamatergic synapses between layer 2/3 and layer 5/6
pyramidal cell layers of the mice PrPFC.
Whole cell voltage clamp recordings were performed to
measure the effects of CB1R activation on excitatory synaptic
responses evoked in the presence of the GABA-A antagonist
picrotoxin (100 mM) by stimulating layer 2/3 to layer 5/6
pyramidal cells synapses. Noteworthy, to reduce as much as
possible polysynaptic events [22], we used a physiological external
Ca2+ concentration (1.2 mM) that in most cases prevented the
occurrences of polysynaptic currents (not shown).
Evoked excitatory postsynaptic currents (eEPSCs) in layer 5/6
were strongly inhibited by bath perfusion of the CB agonist CP
Figure 2. Immunocytochemical localization of mGluR5/DGL-a (A, B) and CB1R/ DGL-a (C, D) in mouse prPFC cortical layers V/VI. Double
preembedding immunogold and immunoperoxidase methods for electron microscopy. (A, B) mGluR5 metal particles (arrows) and DGL-
a immunodeposits colocalized in postsynaptic dendrites (den) and dendritic spines (s). mGluR5 labeling was in perisynaptic and extrasynaptic
membranes. No mGluR5/DGL-a immunoreactivity was observed in presynaptic terminals (T). (C, D) CB1R immunoparticles were on presynaptic
terminals membranes (T) away from synaptic specializations made on postsynaptic DGL-a-immunoreactive dendritic spines (s). Observe that DGL-a-
positive spines also received CB1R-immunonegative synaptic terminals, and that a CB1R-labeled presynaptic terminal (thick arrow) probably of
inhibitory nature (IT in D) made a synapse with a postsynaptic DGL-a-negative dendritic branchlet. Scale bars: 0.5 mm.
doi:10.1371/journal.pone.0000709.g002
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55,940 (10 mM, Fig 3A). The inhibitory effects of the CB agonist
were totally prevented by pretreatment and co-perfusion with the
selective CB1 antagonists SR141716A (10 mM, Fig 3B) demon-
strating the implication of cannabinoid receptors of the CB1R
subtype. The effects of the CB agonist CP55,940 were dose-
dependent with an EC50 of 19560.3 nM (Fig 3C), in agreement
with other reports [30,31]. Taken together, these data show that
the inhibitory effects of the CB agonist are due to the activation of
CB1 receptors.
To functionally assess the origin of the CB1-mediated de-
pression, we measured the coefficient of variation (CV = standard
deviation/mean amplitude) of individual evoked EPSCs. Bath
application of CP55,940 (10 mM) significantly decreased the
coefficient of variation, expressed as 1/CV2 (n = 6, Fig 3D).
Together with our ultrastructural data, these electrophysiological
results are consistent with a presynaptic locus of action of
CB1R.
eCB-mediated LTD in prefrontal cortex pyramidal
cells
The eCB system mediates retrograde long-term synaptic plasticity
at the PrPFC to nucleus accumbens glutamatergic synapses
[28,32–34] and in other brain areas [1]. Based on our present
results showing functional presynaptic CB1R at pyramidal cells
synapses and our ultrastructural data showing the presynaptic
localization of CB1R, we tested the existence of eCB-dependent
plasticity within the PrPFC. We used a stimulation protocol that
Table 1. Percentage of presynaptic and postsynaptic elements immunoreactive for CB1R, mGluR5 or DGL-a.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Protein Profile % of immuno+profiles Particles/mm6SEM
mGluR5+ (DAB)
Postsynaptic DGL-a
Total nu of
profiles
Analyzed area
(mm2)
CB1R Presynaptic (terminals) 51.28% 1.16760.132 87% 63.6% 80+/76- 339.66
mGluR5 Postsynaptic (den-spines) 79.88% 2.01560.11 ---------- 55.1% 135+/34- 257.55
DGL-a Postsynaptic (den-spines) 55.84% 1.28660.16 99% -------- 86+/68- 305.92
The percentage of CB1R-labeled presynaptic compartments relative to postsynaptic mGluR5 and DGL-a is shown. Prelimbic prefrontal cortical sections used for
counting were obtained from 3 adult mice. Electron micrographs were taken at a final magnification of x15,000.
doi:10.1371/journal.pone.0000709.t001..
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Figure 3. Pharmacological characterization of presynaptic CB1R at layer V-VI synapses of the PrPFC. Layer V-VI pyramidal cells were voltage-
clamped and held at -70mV. (A) CB1R-mediated inhibition of evoked transmission. The cannabimimetic CP55,940 (10 mM) reduced evoked EPSCs on
average to 4865 % (n = 6) of basal value. Traces represent the average of 10 consecutive EPSCs taken at the times indicated on the time-course
graph. (B) The inhibitory effects of CP55,940 on evoked EPSCs were blocked by pre-treatment with the selective CB1R antagonist SR141716A (10 mM,
t-test p = 0.0386) in agreement with the involvement of CB1R. (C) Dose response curve measured 20 min after beginning CP55,940 application. Each
point is expressed as the percentage of inhibition of its basal value. The EC50 was 19560.3 nM. (D) The coefficient of variation, expressed as 1/CV2
was reduced following the CP55,940 (p = 0.0107 paired t-test). 1/CV2 was calculated with 60 sweeps i.e. 10 min before and 20 min after CP55,940.
doi:10.1371/journal.pone.0000709.g003
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we first introduced [28] and that is based on naturally occurring
frequencies [35,36]. Stimulation of layer 2/3 PrPFC afferents to
layer 5/6 pyramidal cells (10 min at 10 Hz) induced a robust LTD
of glutamatergic inputs that can be reliably observed when
recording pyramidal cells in the whole cell patch-clamp configu-
ration (Fig 4A left), as well as when recording extracellular field
excitatory post synaptic potentials (fEPSPs, Fig 5A). This LTD was
mediated by eCBs/CB1R since it was completely prevented when
slices were preincubated with the CB1R antagonists AM251
(Fig 4A left). The eCB-LTD was expressed at a presynaptic locus:
first, the coefficient of variation, expressed as 1/CV2, was reduced
following LTD induction (Fig 4A right) and second, the frequency
but not the amplitude of spontaneous EPSCs (sEPSCs) was
reduced following LTD induction (Fig 4B). Finally, we observed
that the basal membrane properties and firing pattern of
pyramidal cells were not affected following induction of LTD
(Fig 4C).
eCB-LTD is mediated by postsynaptic mGluR5
In the PrPFC, eCB-LTD did not require the activation of
NMDAR, D1 or D2 dopamine receptors, as demonstrated by the
lack of effects of a cocktail of antagonist of these receptors (Fig 5A).
Postsynaptic metabotropic receptors (mGluRs) of the mGluR5
subtype translate glutamatergic signaling into eCB retrograde
signaling [28,32]. In the PrPFC synapses, we found that both the
non-subtype selective mGluR antagonist LY341495 (50 mM,
Fig 5C grey bar) and the specific mGluR5 non-competitive
Figure 4. Presynaptic CB1R-mediated LTD in the PrPFC. (A) Left: A 10 min 10 Hz stimulation of layer II-III fibers (arrow) induced a profound long-
term depression of evoked EPSCs recorded in patch-clamped layer V-VI pyramidal neurons. The induction of LTD was completely prevented when
slices were preincubated and tetanized in the presence of the CB1R antagonist AM251 (4 mM). Traces represent the average of 12 consecutive EPSCs
before and 25 minutes after LTD induction in the absence (upper left) or presence (upper right) of AM251. Right: The coefficient of variation, 1/CV2,
was significantly reduced after induction of eCB-LTD (p = 0.0025 paired t-test). Calibration bars: x: 50 ms, y: 100 pA. (B) Representative continuous
3 seconds sweeps showing the spontaneous EPSCs (sEPSCs) recorded before (left) and after eCB-LTD induction (right). The distribution of sEPSCs
inter-event intervals (left panel) but not of their amplitude (right panel) was modified following induction of LTD suggesting a presynaptic
modulation (Kolmogorov-Smirnov test: inter event interval p,0.005, amplitude p=0.507). Calibration bars: x: 100 ms, y: 10 pA. (C) Responses to
hyperpolarizing and depolarizing somatic current pulses of a typical pyramidal neuron in the PFC before and after induction of eCB-LTD. Similar I–V
curves were obtained suggesting that eCB-LTD induction did not change post-synaptic pyramidal neurons properties. Calibration bars: x: 100 ms, y:
25 mV.
doi:10.1371/journal.pone.0000709.g004
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antagonist MPEP (10 mM, Fig 5B) blocked eCB-LTD. Thus, as
previously described at the PrPFC to nucleus accumbens synapses
[28], activation of mGluR5 is necessary to induce eCB-LTD via
a yet unidentified eCB that activates presynaptic CB1R. This
observation underscores the importance of mGluR5 in eCB-
mediated phenomena throughout the brain [1].
Phospholipase C and postsynaptic Ca2+ rise are
necessary for eCB-LTD.
Phospholipase C (PLC) is a primary intracellular effector of both
mGluR1 and mGluR5 group 1 mGluRs [37] and we tested the
effects of the Phospholipase C inhibitor U73122 on eCB-LTD. As
summarized figure 5C (black bar) U73122 (5 mM) completely
blocked eCB-LTD. Activation of PLC-coupled mGluR results in
IP3-mediated release of Ca2+ by intracellular stores [37].
Accordingly, we found that chelation of postsynaptic Ca2+ (with
20 mM BAPTA intrapipette) completely prevented the induction
of eCB-LTD at PrPFC synapses (Fig 5D), as in the nucleus
accumbens synapses [28]. These results strongly indicate that the
intracellular cascade triggered by the stimulation of mGluR5
involves the PLC and that postsynaptic Ca2+ rise is required to
induce eCB-LTD, in accord with a role for postsynaptic mGluR5.
2-AG mediates eCB-dependent LTD in the prefrontal
cortex.
The two main eCBs produced upon neuronal stimulation in the
brain are 2-AG and anandamide [38]. In an attempt to identify the
molecular nature of the eCB responsible for LTD in the PrPFC, we
used a stimulation protocol (5 min at 10 Hz) that was normally sub
threshold to induce LTD in our preparation (Fig 6A,D). We next
took advantage of the recent development of specific inhibitors of the
enzyme degrading 2-AG, Monoacyl Glycerol lipase [39,40]. When
PrPFC slices were perfused with the specific Monoacyl Glycerol
lipase inhibitor URB602 (100 mM) [39,40], the ‘‘5 min at 10Hz’’
protocol induced LTD showing that 2-AG degradation limits the
induction of LTD (Fig 6B-C). In contrast, blockade of the Fatty Acid
Amide Hydrolase, the enzyme that breaks anandamide down, with
the specific inhibitor URB597 (2 mM) had no effect (Fig 6D).
Importantly, we observed that blocking DGL-a with tetrahydrolip-
statin (THL, 10 mM, 2 hours preincubation) strongly inhibited eCB-
LTD (Figure 7). All together these experiments strongly suggest that
2-AG and not anandamide mediates eCB-LTD in the PrPFC.
Finally, in slices pretreated with AM404 (20 mM), an inhibitor of
eCB uptake, the ‘‘5 min at 10 Hz’’ protocol was sufficient to induce
LTD showing that eCB uptake is an important limiting step in the
induction of 2-AG-mediated plasticity (Fig 8).
DISCUSSION
The present study reports several novel findings regarding the eCB
system in the mice PFC. First, we identified several components of
the eCB system at the synapses on layer V/VI pyramidal neurons:
CB1R are located on axon terminals that make contacts with
postsynaptic densities bearing both mGluR5 - a metabotropic
glutamate receptor known for its central role in coupling
glutamate release to eCB-production [1,28,32,41,42] - and
DGL-a , a key enzyme of the synthesis of 2-AG. Second, in
agreement with the molecular composition of the eCB system at
these PFC synapses, we discovered that the eCB-system mediates
a LTD of evoked excitatory responses.
Figure 5. Postsynaptic receptors and transduction pathways involved in eCB-LTD. (A) eCB-LTD was not affected by a mixture of the NMDAR
antagonist MK801 (40 mM), the D1 receptor antagonist SCH23390 (25 mM) and the D2 receptor antagonist sulpiride (25 mM). (B) The mGluR5
antagonist MPEP (10 mM) completely blocked eCB-LTD (C) Bar graph summarizing experiments showing that the non subtype selective group
1mGluR antagonist LY341495 (50 mM) and the Phospholipase C inhibitor U73122 both prevented eCB-LTD induction. 45 min after the end of the
tetanus, the fEPSPs was 76.662.64% (n= 62) of baseline in control and 95.864.85% (n= 12, p = 0.004 t-test) and 96.3366.4% (n= 11, p = 0.0009 t-test)
in LY341495, respectively. (D) eCB-LTD requires postsynaptic Ca2+ rise. Time course of all the experiments performed where the recording pipette was
filled with BAPTA (20 mM, n = 11) and where eCB-LTD was completely blocked.
doi:10.1371/journal.pone.0000709.g005
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The description of the localization of the molecular components
of the eCB-system is a necessary step toward the understanding of
the physiological roles of the eCB system. In a recent study,
Katona and colleagues [29] demonstrated for the first time the
precise anatomical position of CB1R and of DGL-a at the
excitatory synapse of the hippocampus: presynaptic CB1R are
localized opposite to dendritic apparatus expressing DGL-a Our
results confirm and extend those of Katona. In synapse of the
PFC, CB1R and DGL-a are also expressed on opposite sides of –
presumably glutamatergic synapses. In addition, we provide the
first evidences that in the postsynaptic compartments, the DGL-a is
localized closely to mGluR5, a glutamate receptor well known for
Figure 6. Role of 2-AG in eCB-LTD LTD in the PrPFC. (A) Typical experiment showing that a 5 min stimulation at 10 Hz is sub threshold to induce
LTD, even when applied two consecutives times. Calibration bars: x: 10 ms, y: 0.2 mV. (B) Representative experiment showing that 5 min at 10 Hz can
induce LTD when applied after bath perfusion with URB 602 (100 mM). Traces were taken at the time indicated on corresponding graph. Calibration
bars: x: 10 ms, y: 0.2 mV. (C) Summary bar histogram of all the experiments performed where the first tetanus was given in saline and the second
tetanus was given after bath perfusion of URB602. LTD was induced only when URB was present (t-test, p = 0.0271). (D) Averaged time courses of the
experiments in which the 5min at 10Hz protocol was given in control ACSF (open circles) of after pre-treatment with URB597 (2 mM, black triangles)
or URB602 (black circles).
doi:10.1371/journal.pone.0000709.g006
Figure 7. Inhibition of DGL-a, the enzyme that synthesizes 2-AG,
blocked eCB-LTD. Averaged time courses of the experiments in which
the 10 min at 10 Hz protocol was given in control ACSF (open circles) of
after pre-treatment with tetrahydrolipstatin (THL, 10 mM, black circles),
an inhibitor of the DGL-a.
doi:10.1371/journal.pone.0000709.g007
Figure 8. Effects of blocking eCB reuptake on sub threshold tetanus.
Averaged time courses of the experiments in which the 5 min at 10 Hz
protocol was given in control ACSF (open circles) of after pre-treatment
with the eCB reuptake blocker AM404 (20 mM, black circles).
doi:10.1371/journal.pone.0000709.g008
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its key role in eCB-retrograde plasticity. Thus, our data
demonstrate that postsynaptic spines in the PFC contain the two
key proteins necessary to translate glutamatergic signals (mGluR5)
into eCB (DGL-a) [26].
Our electron micrographs also show that presynaptic CB1R
face postsynaptic mGluR5 at PFC synapses. Together, these data
reinforce the proposition that ‘‘this molecular composition of the
eCB system may be a general feature of most glutamatergic
synapses…’’ [29].
Stimulation of layers II/III and/or layers V/VI fibers at 10Hz
induced a remarkably robust LTD of evoked and spontaneous
EPSCs recorded in layers V/VI pyramidal neurons. Thus, as we
first demonstrated at the PFC to accumbens glutamatergic
synapses [28], prolonged stimulation at frequencies around
10Hz is optimal to induced eCB-mediated LTD [32–34,43–45].
The reasons for the efficiency of this frequency range are not clear
but it is possible that this frequency allows for the full activation of
perisynaptic mGluR5 [46]. Noteworthy, similar frequencies have
been recorded in-vivo in behaving rats [35,47,48], underlying the
importance of using physiologically relevant stimuli when studying
synaptic plasticity ex vivo.
The most abundant eCBs released following neuronal synaptic
activity are 2-AG and anandamide [38]. In most brain areas,
pharmacological experiments using blocker of eCB synthesis
suggest that eCB-mediated synaptic plasticity involves 2-AG
rather that anandamide [1,39,40,49–55]. Noteworthy, ananda-
mide but not 2-AG seems to play a predominant role in the
regulation of synaptic plasticity in the striatum [56]. We found that
it is possible to induce eCB-LTD in the PrPFC by applying
subthreshold stimulation in the presence of blockers of either eCBs
reuptake (AM404) or 2-AG degradation [39,40]. In contrast,
blocking anandamide degradation (using the FAAH inhibitor
URB597) had no effect. Thus our data indicate that 2-AG
degradation and eCB reuptake are important limiting steps in the
induction of 2-AG-mediated synaptic plasticity. The prominent
role of 2-AG at PrPFC synapses is supported by our findings that
the enzyme producing 2-AG, the DGL-a and mGluR5 colocalize
in postsynaptic specializations. Interestingly, activation of group 1
mGluRs-such as mGluR5- has been clearly linked to the produc-
tion of 2-AG [42]. Finally we observed that blocking the DGL-
a with THL, strongly inhibited eCB-LTD (Figure 7). We conclude
that 2-AG mediates eCB-LTD in the PrPFC.
Based on the finding that cannabinoids potentiate emotional
learning plasticity in the medial PFC, it has recently been
proposed that the eCB system plays a major role in the neural
circuits underlying emotional learning [21,57]. Moreover, the PFC
plays a central role in adaptive behaviors such as the extinction of
aversive memories [58,59], which is one of the best documented
physiological functions mediated by the eCB system [60,61]. Thus,
our data reinforces the idea that the eCB-system is a critical
component of PFC physiology and that deregulation of eCB-
mediated synaptic plasticity may participate to the etiology of
PFC-related pathologies.
MATERIALS AND METHODS
Animal treatment
Animal experiments accomplished the criteria of the European
Communities Council Directive (86/609/EEC) and the United
States National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Mice (4–6 weeks old male, C57B1/6 strain)
were housed, grouped and acclimatized to laboratory conditions
(12 hr light/dark cycles) 1 week before the experiment and had ad
libitum food and water access.
Slice preparation and electrophysiology
Whole cell patch-clamp and extracellular field recordings were
made from visualized pyramidal cells in coronal slices of mouse
prefrontal cortex. In brief, mouse were anesthetized with
isoflurane and decapitated. The brain was sliced (300 mm) in the
coronal plane using a vibratome (Integraslice, Campden Instru-
ments, Loughborough, UK) and maintained in physiological saline
at 4˚C. Immediately after cutting, slices containing the PrPFC were
stored for 30 min at 32–35uC in artificial cerebrospinal fluid (ACSF)
that contained (in mM): 126 NaCl, 2.5 KCl, 2.4 MgCl2, 1.2 CaCl2,
18 NaHCO3, 1.2 NaH2PO4, and 11 Glucose, and was equilibrated
with 95% O2/5% CO2. Slices were stored at room temperature until
time of recording. For recording, slices were placed in the recording
chamber and superfused (2 ml/min) with ACSF. All experiments
were done at 32–35uC. The superfusion medium contained
picrotoxin (100 mM) to block GABAA receptors. All drugs were
added at the final concentration to the superfusion medium.
To evoke synaptic currents, stimuli (100–150 msec duration)
were delivered at 0.1 Hz through a glass electrode filled with
ACSF and placed either in layer 2/3 or in layer 5/6 as previously
described [22]. No difference was observed between the two sites
of stimulation and thus data were pooled together. Both the EPSC
area and amplitude were measured (graphs depict amplitudes).
For extracellular field experiments, the recording pipette was filled
with ACSF. Both the field excitatory postsynaptic potential (fEPSP)
area and amplitude were measured (graphs depict area). The
glutamatergic nature of the extracellular fEPSP was confirmed at the
end of the experiments through the application of the non-NMDA
ionotropic glutamate receptor antagonist DNQX (20 mM), which
completely blocked the synaptic N2 component without altering the
non-synaptic N1 component (not shown).
For whole cell patch-clamp experiments, layer 5/6 pyramidal
neurons were visualized using an upright microscope with infrared
illumination. Recordings were made with electrodes containing
the following (mM): Cesium Methane-Sulfonate (CH3O3SCs) or
K+Gluconate 128, NaCl 20, MgCl21, EGTA 1, CaCl2 0.3, Na
2+-
ATP 2, Na+-GTP 0.3, Glucose 10 buffered with Hepes 10, pH 7.3,
osmolarity 290 mOsm. Electrode resistance was 4–6 MOhms. For
the BAPTA experiments, 20 mM BAPTA was added to the
intracellular medium.
A 22 mV hyperpolarizing pulse was applied before each
evoked excitatory post-synaptic current (EPSC) in order to
evaluate the access resistance, and those experiments in which
this parameter changed .20% were rejected. Access resistance
compensation was not used and acceptable access resistance was
,25 MOhms. The potential reference of the amplifier was
adjusted to zero prior to breaking into the cell. An Axopatch-1D
(Molecular Device, Sunnyvale, USA) was used to record the data,
which were filtered at 1–2 kHz, digitized at 5 kHz on a DigiData
1200 interface (Molecular Device, Sunnyvale, USA) and collected
on a PC using Clampex 9.2 and analyzed using Clampfit 9.2
(Molecular Device, Sunnyvale, USA).
Spontaneous miniature excitatory postsynaptic currents
(sEPSCs) were recorded in the whole cell voltage-clamp config-
uration using Axoscope 9.2 (Molecular Device, Sunnyvale, USA).
sEPSC amplitude and inter-interval time were detected and
analyzed using Clampfit 9.2 (Molecular Device, Sunnyvale, USA).
For this analysis, a template of sEPSCs generated from averaging
several typical synaptic events was slid along the data trace one
point at a time. At each position, this template is optimally scaled
and offset to fit the data and a detection criterion is calculated.
The detection criterion is the template-scaling factor divided by
the goodness-of-fit at each position. An event is detected when this
criterion exceeds a threshold and reaches a sharp maximum.
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The coefficient of variation (CV) was calculated for as standard
deviation / mean amplitude of individual evoked EPSCs and
expressed as 1/CV2.
Data analysis and materials
All values are given as mean6S.E.M. For field recording/patch-
clamp experiments, n corresponds to the number of individual
cells/slices analyzed, with at least 4 animals included in each
condition. Statistical significance between groups was tested using
the Mann-Whitney U-test. Kolmogorov-Smirnov test was used for
the statistical comparison of the cumulative distributions. All
statistical tests were performed with Kyplotb13 (Koichi Yoshioka)
using a critical probability of p,0.05.
The fitting of concentration response curves were calculated
according to y = {ymax2ymin/1+(x/EC50)n}+ymin (where
ymax = response in the absence of agonist, ymin = response remain-
ing in presence of maximal agonist concentration, x = concentration,
EC50 = concentration of agonist producing 50% of the maximal
response and n = slope) with Kaleidagraph 3.5 software (Synergy
Software, Reading, PA, USA).
Drugs
U73122, picrotoxin, CP55,940, THL and BAPTA from SIGMA
(St. Quentin Fallavier, France) ; AM-251, DNQX, AM404,
MPEP, and 2-amino-2-(2-carboxycyclopropan-1-yl)-3-(dibenzo-
pyran-4-yl) propanoic acid (LY341495) from Tocris (Bristol,
UK). URB 597 and URB 754 were from Cayman (SPI-BIO,
Montigny Le Bretonneux, France). SR141716A was a generous
gift from Sanofi-Aventis Recherche (Montpellier, France). Other
chemicals were from the highest commercial grade available.
Confocal microscopy
Mice (n = 4, 4–6 weeks old male, C57B1/6 strain) were deeply
anesthetized with chloral hydrate (400 mg/kg body weight) and
were transcardially perfused at room temperature (20–25uC) with
PBS, pH 7.4, for 20 sec, followed by 500 ml of 4% formaldehyde
(freshly depolymerized from paraformaldehyde) in 0.1 M phos-
phate buffer (PB), pH 7.4, for 10–15 min. Then, brains were
removed from the skull and postfixed in 4% formaldehyde for up
to 1 hr at room temperature. 50 mm-thick coronal sections cut
from prPFC in a vibratome, were washed and blocked in 0.1 M
PBS containing 3% newborn calf [25]primary antibodies for
2 days at 4uC. We used polyclonal CB1R goat antibodies (3 mg/
ml in 1.5% NCS/PBS) and polyclonal DGL-a guinea pig and
rabbit antibodies (2 mg/ml in 1.5% NCS/PBS) generously
provided by Dr. Masahiko Watanabe (Department of Anatomy,
Hokkaido University School of Medicine, Sapporo, Japan)
[25,26]. Polyclonal rabbit antibodies against mGluR5 (AB5675,
Chemicon, CA, USA) were diluted at 1.36 mg/ml in 1.5% NCS/
PBS. Slices were then washed in blocking solution and incubated
with the following fluorochrome-conjugated secondary antibodies
at working dilutions of 1:800 in 1.5% NCS/PBS: donkey anti-goat
Alexa Fluor-488 (Molecular Probes, Eugene, OR, USA); donkey
anti-rabbit Cy3 (Jackson ImmunoResearch Inc.); goat anti-guinea
pig Alexa Fluor-594 and goat anti-rabbit Alexa Fluor-488
(Molecular Probes, Eugene, OR, USA). Incubations were over-
night at 4uC. Slices were washed again in 0.1 M PBS and then
mounted in Vectashield medium (Vector laboratories, Burlin-
game, USA), coverslipped, and imaged on a laser-scanning
confocal microscope (Olympus Fluoview FV500). Photomicro-
graphs were taken and presented using Adobe Photoshop 7
(Adobe Systems, San Jose, CA, USA).
Double mGluR5/CB1R and DGL-a/CB1R
immunocytochemistry for electron microscopy
Mice (n = 8, 4–6 weeks old male, C57B1/6 strain) were deeply
anesthetized with chloral hydrate (400 mg/kg body weight). The
animals were transcardially perfused with phosphate-buffered
saline (PBS 0.1M, pH 7.4) and then fixed by 500 ml of a fixative
made up of 0.1% glutaraldehyde, 4% formaldehyde (freshly
depolymerized from paraformaldehyde) and 0.2% picric acid in
PBS. Perfusates were used at 4uC.Tissue blocks were extensively
rinsed in 0.1M PBS (pH 7.4). Coronal prPFC vibrosections were
cut at 50 mm and collected in 0.1 M PBS (pH 7.4) at room
temperature. Sections were preincubated in 10% blocking NCS
serum prepared in PBS for 1 h at room temperature and then
incubated overnight at room temperature with rabbit polyclonal
antibodies to mGluR5 (AB5675, Chemicon, CA, USA; 1.36 mg/
ml diluted in 1.5% NCS/PBS), or with polyclonal guinea pig
antibodies to DGL-a (2 mg/ml in 1.5% NCS/PBS) generously gifted
by Dr. Masahiko Watanabe (Department of Anatomy, Hokkaido
University School of Medicine, Sapporo, Japan) for 2 days at 4uC.
The localization of mGluR5 or DGL-a was carried out by means of
a preembedding immunoperoxidase method. Briefly, prPFC
sections were incubated sequentially at room temperature with
a biotinylated secondary antibodies and avidin-biotin complex
(ABC, Elite, Vector laboratories, Burlingame, CA, USA), each for
1 h. The immunoreaction was visualized with 0.05% 3,39-
diaminobenzidine (DAB)/ 0.01% hydrogen peroxide as chromogen.
The preembedding silver-intensified immunogold method de-
scribed previously [27] was used for the localization of CB1R in
prPFC sections processed for the immunoperoxidase method with
either mGluR5 or DGL-a antiserum. Following incubation with
the primary polyclonal goat antibodies against CB1R (3 mg/ml in
1.5% NCS/PBS; generously gifted by Dr. Masahiko Watanabe,
Department of Anatomy, Hokkaido University School of Medi-
cine, Sapporo, Japan) for 2 days, prPFC sections were incubated
with 1.4 nm gold-labeled rabbit anti-goat IgG (Fab’ fragment,
1:100, Nanoprobes Inc., Stony Brook, NY, USA) diluted in 1%
NCS/PBS for 4 hours at room temperature. In another set of
experiments, mGluR5/DGL-a and DGL-a/mGluR5 were colo-
calized by the preembedding immunogold and immunoperoxidase
methods, being the first protein of each combination revealed by
silver-intensified gold particles (mGluR5: 1.4 nm gold-labeled goat
anti-rabbit IgG, Fab’ fragment, 1:100; DGL-a: 1.4 nm gold-
labeled goat anti-guinea pig IgG, Fab’ fragment, 1:100; Nanoprobes
Inc., Stony Brook, NY, USA). PrPFC tissue was subsequently
postfixed in 1% glutaraldehyde for 10 min, rinsed extensively in
double-distilled water, and gold particles were silver intensified with
an HQ Silver kit (Nanoprobes Inc.) for about 8 min.
Successfully double stained sections were osmicated (1% OsO4
in 0.1 M PB, pH 7.4, 20 min), dehydrated in graded alcohols to
propylene oxide and plastic-embedded flat in Epon 812. Ultrathin
sections were collected on mesh nickel grids, stained with uranyl
acetate and lead citrate, and examined in a JEOL (Peabody, MA)
X-100 electron microscope.
Preparations were photographed by using standard electron
microscopy negative plates. Figure compositions were scanned at
300 dots per inch (dpi). Labeling and minor adjustments in
contrast and brightness were made with Adobe Photoshop (7.0,
Adobe Systems, San Jose, CA, USA).
Quantitative analysis
PrPFC sections from 3 mice were analyzed. Electron micrographs
were taken at a final magnification of x15.000 from 150 mm-grid
squares showing good and reproducible DAB immunoreaction
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and silver-intensified gold particles for any condition studied.
Image-J (version 1.36) was used to measure the membrane length.
Positive labeling was considered if immunoparticles were in close
proximity to the plasmalemma. Metal particles on membranes and
positive immunoreactive profiles were visualized and counted
manually. The total area studied for CB1R was >340 mm2,
mGluR5>258 mm2 and DGL-a >306 mm2. Density of immuno-
particles were averaged from different samples and presented as
mean6SEM.
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